CFTR and cystic fibrosis: It is the authors’ opinions that key questions that must be answered before airway gene therapy can be translated to the clinic involve clearly demonstrating long-term efficacy and the safety of LPC and LV delivery in a CF lung, the ability to re-dose to boost CFTR gene expression levels, and the ability to translate these techniques into human-sized lungs.